Clinical Trials Logo

Corneal Ectasia clinical trials

View clinical trials related to Corneal Ectasia.

Filter by:

NCT ID: NCT06348368 Completed - Corneal Ectasia Clinical Trials

Refractive and Corneal Topographic Characteristics in Upper Egypt Children With High Cylinder

Start date: January 1, 2023
Phase:
Study type: Observational

Refractive and Corneal Topographic Characteristics in upper Egypt children with high cylinder: A cross sectional study

NCT ID: NCT06347900 Recruiting - Corneal Ectasia Clinical Trials

Corneal Topographic Changes in Different Grades of OSA

Start date: January 1, 2024
Phase:
Study type: Observational

Corneal topographic parameters in different degrees of obstructive sleep apnea

NCT ID: NCT05691335 Completed - Corneal Ectasia Clinical Trials

Three Different Cross-linking Protocols for Treatment of Pediatric Keratoconus

Start date: June 1, 2018
Phase: N/A
Study type: Interventional

comparison between standard cross-linking protocol and accelerated and transepithelial cross-linking

NCT ID: NCT05241145 Completed - Keratoconus Clinical Trials

Safety and Preliminary Efficacy of IVMED-80 Eye Drops in Keratoconus Patients

Start date: February 8, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

We investigated the use of a copper sulfate eye drop (IVMED-80) for the treatment of keratoconus. Preliminary laboratory data shows that the addition of copper sulfate increase crosslinking of the structural proteins of the cornea thereby halting the progressing corneal thinning and bulging seen in keratoconus. We conducted a Phase 1/2a study to evaluate the safety and preliminary efficacy of a 6-week and a 16-week regimen using IVMED-80 and studied its impact on ocular safety and the change/progression in patients' vision and clinical measurements.

NCT ID: NCT05027295 Recruiting - Keratoconus Clinical Trials

Accelerated Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Pulse or Continuous UV-A Light

Start date: July 30, 2021
Phase: Phase 3
Study type: Interventional

Corneal collagen crosslinking has been demonstrated as an effective method of reducing progression of both keratoconus and post-refractive corneal ectasia, as well as decreasing the steepness of the cornea in these pathologies. Performing an accelerated CXL procedure with pulsed UVA light may increase the oxygenation of the cornea, which may improve the crosslinking efficacy.

NCT ID: NCT04905108 Recruiting - Keratoconus Clinical Trials

Transepithelial (Epi-on) Corneal Collagen Crosslinking to Treat Keratoconus and Corneal Ectasia

Start date: June 2, 2021
Phase: Phase 3
Study type: Interventional

Corneal collagen crosslinking (CXL) has been demonstrated as an effective method of reducing progression of both keratoconus and corneal ectasia after surgery, as well as possibly decreasing the steepness of the cornea in these pathologies. Transepithelial crosslinking in which the epithelium is not removed has been proposed to offer a number of advantages over traditional crosslinking including an increased safety profile by reducing the risk for infection and scarring, faster visual recovery and improved patient comfort in the early postoperative healing period.

NCT ID: NCT04897503 Recruiting - Keratoconus Clinical Trials

Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Riboflavin/Dextran or Riboflavin/Methylcellulose

CXL
Start date: April 16, 2021
Phase: Phase 3
Study type: Interventional

This study is being conducted to evaluate the safety and efficacy of isotonic riboflavin for corneal collagen crosslinking for keratoconus and corneal ectasia. will determine the safety and efficacy of corneal collagen crosslinking (CXL) performed with two different riboflavin formulations for reducing corneal curvature.

NCT ID: NCT04763785 Active, not recruiting - Cataract Clinical Trials

Development of a Keratoconus Detection Algorithm by Deep Learning Analysis and Its Validation on Eyestar Images

DKDA
Start date: May 11, 2021
Phase:
Study type: Observational

Monocentric clinical study to develop an imaging analysis algorithm for the Eyestar 900 to identify keratoconus corneas and improve biometry for intraocular lens calculations

NCT ID: NCT04698590 Active, not recruiting - Keratoconus Clinical Trials

Wavefront Guided Scleral Lenses for Keratoconus and Irregular Astigmatism

WFG Sclerals
Start date: January 15, 2021
Phase: N/A
Study type: Interventional

Aberrations are the spreading of light from a point focus. Aberrations of the eyes can be objectively evaluated with a wavefront aberrometer. Lower order aberrations such as defocus and astigmatism can be corrected with glasses and traditional/disposable soft contact lenses. Patients with ectatic corneal disease, such as keratoconus, or irregular astigmatism cause by surgery, trauma or disease, experience vision that is unlikely to be adequately corrected with glasses or disposable soft contact lenses due to higher order aberrations (HOA). HOA's cause halos, flare, glare, starbursts, doubling, smearing or ghosting of vision. Specialty contact lenses, such as scleral lenses, can be used to mask the irregularity of the cornea, reducing HOA's and improving vision. In many patients the resultant vision, though improved, still has some level of residual HOA's affecting the quality of vision. Custom scleral lenses with customized wavefront guided optics can be used to reduce residual HOA's and improve vision further. These lenses have been referred to as higher order aberration correcting scleral lenses or HOA correcting sclerals and wavefront guided scleral lenses or WFG sclerals.

NCT ID: NCT04667572 Active, not recruiting - Keratoconus Clinical Trials

Safety & Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution

Start date: February 1, 2021
Phase: Phase 1
Study type: Interventional

Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-linking in Eyes With Corneal Thinning Conditions